Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "Canada"

331 News Found

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
News | June 03, 2022

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS

Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022


European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer
Drug Approval | May 25, 2022

European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer

This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC


Cytel designed and led TOGETHER trial wins Clinical Trial award
News | May 18, 2022

Cytel designed and led TOGETHER trial wins Clinical Trial award

Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills


Agilent companion diagnostic expands CE-IVD Mark in Europe to include cervical cancer
Medical Device | May 18, 2022

Agilent companion diagnostic expands CE-IVD Mark in Europe to include cervical cancer

Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020


Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years
Drug Approval | May 18, 2022

Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years

Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series


Jawed Zia appointed CEO of Cadila Pharmaceuticals Domestic Prescription Business
People | May 14, 2022

Jawed Zia appointed CEO of Cadila Pharmaceuticals Domestic Prescription Business

A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business


Quality issues force Novartis to suspend production of radioligand therapy medicines
News | May 08, 2022

Quality issues force Novartis to suspend production of radioligand therapy medicines

The production suspension impacts commercial and clinical trial supply


Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India
Biotech | May 04, 2022

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India

Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication


Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
Biotech | April 26, 2022

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)


Sinocompound announce new licencing agreement with Dalhousie university
Biotech | April 15, 2022

Sinocompound announce new licencing agreement with Dalhousie university

The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University